Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates
Anemia, Neonatal, Intracranial Hemorrhages, Necrotizing Enterocolitis
About this trial
This is an interventional prevention trial for Anemia, Neonatal focused on measuring Umbilical Cord Blood, Autologous Umbilical Cord Blood Transfusion, Prematurity Complications, Infant, Premature, Diseases, Infant, Newborn, Diseases, Hematologic Diseases, Lung Diseases, Central Nervous System Diseases, Gastrointestinal Tract Diseases, Vascular Diseases, Retinopathies, Neonates, Prevention,Treatment
Eligibility Criteria
Inclusion Criteria:
- preterm neonates less than 34 weeks of gestation, who developed anemia of prematurity,
- available unit of autologous umbilical cord blood
Exclusion Criteria:
- major congenital or chromosomal abnormalities,
- intrauterine infection,
- cyanotic heart defect,
- chronic intrauterine hypoxia (defined as growth retardation or pathologies of placental perfusion),
- incompatibilities in main blood groups and Rh antygen,
- lack of parental consent for enrollment to the study,
- contraindications for cord blood collection (lack of consent, amniotic fluid leakage for longer than 6 hours or physical complications in the cord blood harvesting).
Sites / Locations
- Department of Neonatology of Pomeranian Medical University in Szczecin, Poland
Arms of the Study
Arm 1
Arm 2
Active Comparator
Sham Comparator
Autologous cord blood transfusion
Standard treatment for neonatal anemia
Treatment Group 1 Interventions: collected autologous whole cord blood at birth will be transfused for the preterm neonate
Treatment Group 2 Interventions: transfusion of allogeneic whole peripheral blood or any of its components at a time of anemia of prematurity development